Table 3 The concomitant use of cDMARD/steroid medications with biologics
From: Treatment persistence of biologics among patients with psoriatic arthritis
| Â | Treatment periods | P value | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adalimumab | Etanercept | Infliximab | Ustekinumab | Golimumab | Secukinumab | |||||||||
Concomitant MTX | No | 642 | 75.7% | 807 | 81.6% | 159 | 68.2% | 210 | 87.5% | 267 | 75.0% | 244 | 83.6% | 0.001 |
Yes | 206 | 24.3% | 182 | 18.4% | 74 | 31.8% | 30 | 12.5% | 89 | 25.0% | 48 | 16.4% | ||
Concomitant other cDMARDs | No | 783 | 92.3% | 919 | 92.9% | 210 | 90.1% | 221 | 92.1% | 311 | 87.4% | 264 | 90.4% | 0.03 |
Yes | 65 | 7.7% | 70 | 7.1% | 23 | 9.9% | 19 | 7.9% | 45 | 12.6% | 28 | 9.6% | ||
MTX before | No | 163 | 19.2% | 177 | 17.9% | 47 | 20.2% | 43 | 17.9% | 44 | 12.4% | 40 | 13.7% | 0.03 |
Yes | 685 | 80.8% | 812 | 82.1% | 186 | 79.8% | 197 | 82.1% | 312 | 87.6% | 252 | 86.3% | ||
cDMARDs before | No | 322 | 38.0% | 319 | 32.3% | 106 | 45.5% | 103 | 42.9% | 101 | 28.4% | 102 | 34.9% | 0.001 |
Yes | 526 | 62.0% | 670 | 67.7% | 127 | 54.5% | 137 | 57.1% | 255 | 71.6% | 190 | 65.1% | ||
GC | No | 510 | 60.1% | 633 | 64.0% | 132 | 56.7% | 141 | 58.8% | 195 | 54.8% | 196 | 67.1% | 0.03 |
Yes | 338 | 39.9% | 356 | 36.0% | 101 | 43.3% | 99 | 41.3% | 161 | 45.2% | 96 | 32.9% | ||